|
||
| |||||||
|
This report comprehensively examines the emerging technologies underlying predictive pharmacogenomics and personalized medicine, the leading companies applying these technologies, and the impact predictive pharmacogenomics will have on medicine and pharmaceutical markets. The report is based on interviews with more than 20 experts, who helped us shape the focus of this study. More than 30 companies and their technologies are discussed in detail, and contact information and areas of specialization are supplied for more than 80 companies overall. Case studies of the impact of pharmacogenomic technologies on sales of specific drugs and diagnostics are presented, and we discuss the business and scientific issues shaping this field and how this area is most likely to evolve. Companies discussed in detail include Celera Genomics, diaDexus, DNAPrint, deCODE Genetics, Gemini Genomics, Genaissance Pharmaceuticals, Gene Logic, Genentech, Genome Therapeutics, Genomica, Genset, Golden Helix, GlaxoSmithKline, Genzyme Genetics, Incyte Genomics, Millennium Pharmaceuticals, Myriad Genetics, Novartis, Oxagen, Quintiles, and Variagenics. Thought Leaders Interviewed for This Report: Andrea Califano, First Genetic Trust; Claire J. Allan, GlaxoSmithKline; and Stephen Friend, Rosetta Inpharmatics, and others. Publication date/length: May 2002; approximately 180 pages. Publisher: Cambridge Healthtech Institute To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_Cambridge_Healthtech_Institute_29.html#a484
|
|
| ||||||||